A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL-GROUP, PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF PT027 COMPARED TO PT007 ADMINISTERED AS NEEDED IN RESPONSE TO SYMPTOMS IN SYMPTOMATIC ADULTS AND CHILDREN 4 YEARS OF AGE OR OLDER WITH ASTHMA (MANDALA)

Intervention/treatment:
BUDESONIDE/ ALBUTEROL
Medical condition:
ASTHMA
Protocol code:
AV003
Control number:
222377
Status:
Closed
Approved:
December 21, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03769090
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
4 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Chief Medical Officer
Organization
Avillion LLP
Phone:
+44 (0)203 764 9530
Sponsor
BOND AVILLION 2 DEVELOPMENT LP

Locations

British Columbia

Research Site
Vancouver, British Columbia, V5Z 4E1

Ontario

Research Site
Ajax, Ontario, L1S 2J5
Research Site
Burlington, Ontario, L7N 3V2
Research Site
Greater Sudbury, Ontario, P3A 1W8
Research Site
London, Ontario, N5W 6A2
Research Site
Newmarket, Ontario, L3Y5G8
Research Site
Toronto, Ontario, M9V 4B4
Research Site
Waterloo, Ontario, N2J 1C4
Research Site
Windsor, Ontario, N8X 1T3

Quebec

Research Site
Québec, Quebec, C1G 3Y8

Results

See the results from the trial NCT03769090. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?